Core Viewpoint - China Sanjiang Chemical (02198) has entered into a purchase agreement with Jiahu Energy Chemical Company (600273) for the supply of ammonia water, effective from January 1, 2026, to December 31, 2026, which aims to regulate the supplier-customer relationship between the two companies [1] Group 1: Agreement Details - The agreement includes the supply of ammonia water, a byproduct generated during the production process [1] - The collaboration is non-exclusive and aims to create new sales avenues for ammonia water due to the proximity of both companies' production bases [1] - The agreement is expected to reduce transportation costs for supplying ammonia water, benefiting both companies [1]

（编辑 丛可心 袁冠琳） 证券日报网讯 12月25日，嘉化能源在互动平台回答投资者提问时表示，公司一贯在巩固现有循环产业 的同时，不断强化优势业务板块的竞争力，有序推进重点项目建设，保障提升主要产品系列的产能，夯 实核心业务板块未来发展的竞争力，抓住绿色能源发展历史机遇，重点发展以氢能等绿色可持续新能源 产业，推动公司高质量发展。同时，注重以分红、回购、注销等多措并举回报投资者。 ...

浙江嘉化能源化工股份有限公司 2025 年第三次临时股东会会议资料 嘉化能源 2025 年第三次临时股东会会议资料 二〇二五年十二月 股票代码：SH600273 1 / 31 嘉化能源 2025 年第三次临时股东会会议资料 目 录 | 1、嘉化能源 | 2025 年第三次临时股东会会议须知 | 3 | | --- | --- | --- | | 2、嘉化能源 | 2025 年第三次临时股东会会议议程 | 5 | | 3、各议案内容 | | 7 | 股票代码：SH600273 2 / 31 嘉化能源 2025 年第三次临时股东会会议资料 浙江嘉化能源化工股份有限公司 2025 年第三次临时股东会会议须知 尊敬的各位股东及股东代表： 欢迎您来参加浙江嘉化能源化工股份有限公司 2025 年第三次临时股东会。 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证大会 的顺利进行，根据《公司章程》、公司《股东会议事规则》及相关法律法规和规定 特制定本须知。 一、董事会以维护股东的合法权益、确保大会正常秩序和议事效率为原则，认 真履行《公司章程》中规定的职责。 二、参加大会的股东请按规定出示股东账户卡，身份证 ...

Core Viewpoint - Jiahuan Energy is a core enterprise in the China Chemical New Materials (Jiaxing) Park, focusing on a circular economy model that integrates energy, chemicals, and new chemical materials into its industrial chain [1][3]. Group 1: Company Overview - Jiahuan Energy has established a circular economy model that includes both internal and external cycles, enhancing resource and energy utilization while reducing costs and improving operational efficiency [3]. - The company is a leading producer of fatty alcohols, benefiting from a stable supply chain and a mature production process, with a domestic market demand of approximately 1 million tons per year and a compound annual growth rate of 3-5% [1][4][5]. Group 2: Production and Capacity - The second phase of the fatty alcohol production line is currently in equipment debugging, with expected capacity release next year, and the company has coordinated with downstream customers for capacity absorption [5][6]. - The PVC second phase has entered trial production, aimed at ensuring stable operation of the chlor-alkali unit and enhancing the overall value of the industrial chain [2][8]. Group 3: Financial Strategy - The company maintains a policy of continuous cash dividends and share buybacks, reflecting its commitment to stable profitability and cash flow management [2][7]. - All related party transactions are essential for production operations and are conducted at market prices, ensuring fairness and compliance with necessary review procedures [6]. Group 4: Market Dynamics - The price of palm oil, a key raw material for fatty alcohols, has been high due to increased demand from downstream sectors and reduced supply caused by seasonal production declines in Indonesia [4][5]. - The company’s stable partnerships with upstream and downstream players contribute to its ability to maintain quality and meet market demands effectively [5].

Core Viewpoint - The China Securities 1000 Value ETF (562530) opened down 1.00% at 1.286 yuan, reflecting market volatility and performance of its underlying assets [1] Group 1: ETF Performance - The China Securities 1000 Value ETF (562530) has a performance benchmark based on the China Securities Intelligent Selection 1000 Value Steady Strategy Index [1] - Since its inception on July 28, 2022, the fund has achieved a return of 29.92% [1] - The fund's return over the past month has been -2.91% [1] Group 2: Top Holdings - Key holdings in the ETF include: - Shangfeng Cement, which opened up 0.82% [1] - Mingtai Aluminum, which decreased by 0.07% [1] - Camel Group, which increased by 0.56% [1] - Oriental Tower, which rose by 0.06% [1] - CIMC Vehicles, which fell by 0.48% [1] - Yingqu Technology, which gained 1.12% [1] - Changjiang Media, which decreased by 0.11% [1] - Sifang Holdings, which increased by 1.34% [1] - Mulinsen, which fell by 0.22% [1] - Jiahua Energy, which rose by 0.24% [1]

（编辑 丛可心） 证券日报网讯 12月15日，嘉化能源在互动平台回答投资者提问时表示，2024年2月20日，公司注销回购 股份10900000股。到2024年末，每股净资产7.29元，较上年末增长3.11%。本年度，公司已于2025年6月 16日注销回购股份34165685股，在其余数据保持不变的假设下，预计2025年末每股净资产将有所增加。 ...

证券日报网讯 12月12日晚间，嘉化能源发布公告称，为满足各全资控股子公司及参股公司2026年日常 生产经营及项目建设的资金需求，降低公司整体融资成本，公司及全资子公司拟为直接或间接控制的全 资及控股子公司（包括已设立和将来设立、收购的全资及控股子公司）及参股公司，提供合计不超过人 民币50亿元融资担保，自公司股东会审议通过之日起一年内可在额度内签署担保协议。 （文章来源：证券日报） ...

Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

以下是第一财经对一些重要公告的汇总，供投资者参考。 【品大事】 隆盛科技：拟3.5亿元投建具身智能机器人创新中心项目 3连板中源家居：股票价格短期波动较大 存在非理性炒作风险 中源家居公告，公司股票价格短期波动较大，短期涨幅显著高于同期上证指数，存在非理性炒作风险，可能存在短期涨幅较大后的大幅下跌风险。公司目前 生产经营活动正常，主营业务未发生重大变化，外部经营环境存在较大不确定性。公司不存在应披露而未披露的重大信息，不存在影响公司股票交易价格异 常波动的重大事项。 恒瑞医药：HRS9531注射液临床试验获批准 针对MASH适应症全球暂无同类药物获批上市 恒瑞医药公告称，子公司福建盛迪医药有限公司收到国家药监局核准签发的HRS9531注射液的《药物临床试验批准通知书》，将于近期开展临床试验。 HRS9531注射液是具有全球自主知识产权的新型靶向抑胃肽受体（GIPR）和胰高血糖素样肽-1受体（GLP-1R）的双激动剂，可在体内调节糖脂代谢、抑制 食欲和增强胰岛素敏感性，从而起到改善血糖和减轻体重的效果。对于代谢功能障碍相关脂肪性肝炎（MASH）患者，HRS9531注射液有望通过改善肝脏脂 质堆积、减轻炎症反应及 ...

一、通知债权人的原由 为进一步优化浙江嘉化能源化工股份有限公司（以下简称"公司"或"嘉化能 源"）管理架构，减少股权层级，提高经营管理效率、资源有效共享，公司将吸收 合并全资子公司浙江嘉化双氧水有限公司（以下简称"双氧水"）。本次吸收合并 完成后，双氧水独立法人资格将被注销，双氧水拥有或享受的所有资产、债权、人 员、利益以及所承担的责任、债务全部由公司承继，公司将作为经营主体对吸收的 资产和业务进行管理。 本事项已经公司第十届董事会第十五次会议审议通过，详见公司于 2025 年 12 月 13 日在指定媒体披露的《关于吸收合并全资子公司的公告》，尚需提交公司股东 会审议。 二、需债权人知晓的相关信息 根据《中华人民共和国公司法》等相关法律、法规的规定，合并双方债权人自 接到通知之日起 30 日内，未接到通知的自本公告刊登之日起 45 日内，均有权凭有 效债权证明文件及凭证向公司要求清偿债务或要求公司提供相应担保。债权人如逾 期未向公司申报债权，不会因此影响其债权的有效性，相关债务（义务）将由公司 根据原债权文件的约定继续履行。 证券代码：600273 股票简称：嘉化能源 编号：2025-071 浙江嘉化能源化 ...